Why Pasithea Therapeutics (KTTA) Stock Is Suddenly On Fire Today

Benzinga_recent_news11-26

Pasithea Therapeutics Corp (NASDAQ:KTTA) shares are trading sharply higher Wednesday morning after a string of upbeat updates on its lead drug candidate, PAS-004, capped by a new $1 million grant from...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2586266924?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/26/Gloves--Test-And-Doctor-With-Medicine--S.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-11-26 23:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586266924","market":"hk","top_or_hot":-1,"title":"Why Pasithea Therapeutics (KTTA) Stock Is Suddenly On Fire Today","media":"Benzinga_recent_news","content":"<div>\n<p>Pasithea Therapeutics Corp (NASDAQ:KTTA) shares are trading sharply higher Wednesday morning after a string of upbeat updates on its lead drug candidate, PAS-004, capped by a new $1 million grant from...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/25/11/49087255/why-pasithea-therapeutics-ktta-stock-is-suddenly-on-fire-today\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pasithea Therapeutics (KTTA) Stock Is Suddenly On Fire Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pasithea Therapeutics (KTTA) Stock Is Suddenly On Fire Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-26 23:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/25/11/49087255/why-pasithea-therapeutics-ktta-stock-is-suddenly-on-fire-today><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pasithea Therapeutics Corp (NASDAQ:KTTA) shares are trading sharply higher Wednesday morning after a string of upbeat updates on its lead drug candidate, PAS-004, capped by a new $1 million grant from...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/25/11/49087255/why-pasithea-therapeutics-ktta-stock-is-suddenly-on-fire-today\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KTTA","symbol_name":"Pasithea Therapeutics Corp.","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/11/49087255/why-pasithea-therapeutics-ktta-stock-is-suddenly-on-fire-today","article_id":"2586266924","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/26/Gloves--Test-And-Doctor-With-Medicine--S.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/11/49087255/why-pasithea-therapeutics-ktta-stock-is-suddenly-on-fire-today","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2586266924","pubTimestamp":1764172620,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Pasithea Therapeutics Corp (NASDAQ: KTTA) shares are trading sharply higher Wednesday following a string of upbeat updates.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"KTTA":"Pasithea Therapeutics Corp.","BK4139":"生物科技"},"translate_title":"为什么Pasithea Therapeutics(KTTA)股票今天突然火爆","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KTTA":1.5},"content_text":"Pasithea Therapeutics Corp (NASDAQ:KTTA) shares are trading sharply higher Wednesday morning after a string of upbeat updates on its lead drug candidate, PAS-004, capped by a new $1 million grant from the ALS Association. Here’s what investors need to know.\nWhat To Know: The Hoffman ALS Clinical Trial Award will fund a clinical study evaluating the efficacy, safety and tolerability of PAS-004 in patients with amyotrophic lateral sclerosis, expanding the drug's reach into a third serious neurological indication.\nInvestors are reacting to a three-day run of news around PAS-004. On Monday, Pasithea reported completion of Cohort 7 in its ongoing Phase 1 trial in advanced solid tumors, showing no treatment-related adverse events, dose-proportional pharmacokinetics and pharmacodynamic data consistent with continuous MAPK pathway suppression.\nThe safety committee cleared escalation to Cohort 8. On Friday, the company released positive pharmacokinetic data from a separate Phase 1/1b study in adult NF1 patients, where a new tablet formulation delivered more favorable exposure than capsules at lower doses with reduced variability.\nWhile PAS-004 remains in early-stage development and regulatory approval is still years away, the rapid cadence of positive data and the ALS Association's non-dilutive funding have improved sentiment around Pasithea's pipeline prospects.\nBenzinga Edge Rankings: Benzinga Edge currently assigns KTTA a Momentum score of 3.51, with no Value, Growth or Quality rankings yet available and negative signals across its short-, medium- and long-term price trends.\nKTTA Price Action: Pasithea Therapeutics shares were up 118% at $1.42 at the time of publication on Wednesday, according to Benzinga Pro data.\nRead Also: AstraZeneca Wins FDA Nod For Imfinzi Combination Regimen In Tough-To-Treat Stomach Cancers\nBesides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. \nFor example, in Pasithea Therapeutics’ case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.\nImage: Shutterstock\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586266924","isCrawlerRequest":true}